Switch theme
Sign up to access all valuation multiples
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
2011
147
LTM Revenue $9.7M
LTM EBITDA -$167M
-$109M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Caribou Biosciences has a last 12-month revenue of $9.7M and a last 12-month EBITDA of -$167M.
In the most recent fiscal year, Caribou Biosciences achieved revenue of $10.0M and an EBITDA of -$163M.
Caribou Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Caribou Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $34.5M | $10.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$113M | -$163M | XXX | XXX | XXX |
| EBITDA Margin | -326% | -1628% | XXX | XXX | XXX |
| Net Profit | -$99.4M | -$102M | XXX | XXX | XXX |
| Net Margin | -288% | -1021% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Caribou Biosciences's stock price is $1.
Caribou Biosciences has current market cap of $74.4M, and EV of -$109M.
See Caribou Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$109M | $74.4M | XXX | XXX | XXX | XXX | $-1.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Caribou Biosciences has market cap of $74.4M and EV of -$109M.
Caribou Biosciences's trades at -11.1x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.
Analysts estimate Caribou Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Caribou Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$109M | XXX | XXX | XXX |
| EV/Revenue | -10.9x | XXX | XXX | XXX |
| EV/EBITDA | 0.7x | XXX | XXX | XXX |
| P/E | -0.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCaribou Biosciences's NTM/LTM revenue growth is 42%
Caribou Biosciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Caribou Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Caribou Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Caribou Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -71% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1628% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1586% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 465% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1302% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1767% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caribou Biosciences acquired XXX companies to date.
Last acquisition by Caribou Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Caribou Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Caribou Biosciences founded? | Caribou Biosciences was founded in 2011. |
| Where is Caribou Biosciences headquartered? | Caribou Biosciences is headquartered in United States of America. |
| How many employees does Caribou Biosciences have? | As of today, Caribou Biosciences has 147 employees. |
| Who is the CEO of Caribou Biosciences? | Caribou Biosciences's CEO is Dr. Rachel Haurwitz, PhD. |
| Is Caribou Biosciences publicy listed? | Yes, Caribou Biosciences is a public company listed on NAS. |
| What is the stock symbol of Caribou Biosciences? | Caribou Biosciences trades under CRBU ticker. |
| When did Caribou Biosciences go public? | Caribou Biosciences went public in 2021. |
| Who are competitors of Caribou Biosciences? | Similar companies to Caribou Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Caribou Biosciences? | Caribou Biosciences's current market cap is $74.4M |
| What is the current revenue of Caribou Biosciences? | Caribou Biosciences's last 12-month revenue is $9.7M. |
| What is the current EBITDA of Caribou Biosciences? | Caribou Biosciences's last 12-month EBITDA is -$167M. |
| What is the current EV/Revenue multiple of Caribou Biosciences? | Current revenue multiple of Caribou Biosciences is -11.1x. |
| What is the current EV/EBITDA multiple of Caribou Biosciences? | Current EBITDA multiple of Caribou Biosciences is 0.6x. |
| What is the current revenue growth of Caribou Biosciences? | Caribou Biosciences revenue growth between 2023 and 2024 was -71%. |
| Is Caribou Biosciences profitable? | Yes, Caribou Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
